Onconova Therapeutics (ONTX) Sets New 1-Year Low at $1.45

Onconova Therapeutics Inc (NASDAQ:ONTX) shares reached a new 52-week low during trading on Thursday . The company traded as low as $1.45 and last traded at $1.48, with a volume of 101100 shares changing hands. The stock had previously closed at $1.51.

A number of research analysts have recently commented on the company. Maxim Group reiterated a “buy” rating and issued a $6.00 price objective on shares of Onconova Therapeutics in a report on Thursday, November 2nd. HC Wainwright initiated coverage on Onconova Therapeutics in a research note on Monday, October 9th. They set a “buy” rating and a $6.00 price target on the stock. Finally, ValuEngine upgraded Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $7.33.

Onconova Therapeutics (NASDAQ:ONTX) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.29 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 2,855.94%. analysts anticipate that Onconova Therapeutics Inc will post -2.82 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in ONTX. 683 Capital Management LLC grew its stake in shares of Onconova Therapeutics by 21.0% in the 3rd quarter. 683 Capital Management LLC now owns 375,000 shares of the biopharmaceutical company’s stock valued at $641,000 after purchasing an additional 65,140 shares during the last quarter. Sabby Management LLC grew its stake in shares of Onconova Therapeutics by 104.0% in the 2nd quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock valued at $1,693,000 after purchasing an additional 399,640 shares during the last quarter. Tyndall Capital Partners L P grew its stake in shares of Onconova Therapeutics by 91.4% in the 2nd quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock valued at $2,154,000 after purchasing an additional 476,190 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Onconova Therapeutics by 58.4% in the 2nd quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 32,418 shares during the last quarter. Hedge funds and other institutional investors own 25.44% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Onconova Therapeutics (ONTX) Sets New 1-Year Low at $1.45” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thestockobserver.com/2017/12/07/onconova-therapeutics-ontx-sets-new-1-year-low-at-1-45.html.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Receive News & Ratings for Onconova Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply